AR111346A1 - Compuesto peptídico con acción activante sobre receptores gip - Google Patents
Compuesto peptídico con acción activante sobre receptores gipInfo
- Publication number
- AR111346A1 AR111346A1 ARP180100762A ARP180100762A AR111346A1 AR 111346 A1 AR111346 A1 AR 111346A1 AR P180100762 A ARP180100762 A AR P180100762A AR P180100762 A ARP180100762 A AR P180100762A AR 111346 A1 AR111346 A1 AR 111346A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptide compound
- activating action
- gip receptors
- medicament
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000003213 activating effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente proporciona un compuesto peptídico que tiene una acción activante sobre los receptores de GIP y el uso del compuesto peptídico como un medicamento. Específicamente, se proporcionan un péptido que contiene una secuencia representada por la fórmula (1) o una de sus sales y un medicamento que lo comprende: P¹-Tyr-A²-Glu-Gly-Thr-A⁶-A⁷-A⁸-A⁹-A¹⁰-A¹¹-A¹²-A¹³-A¹⁴-A¹⁵-A¹⁶-A¹⁷-A¹⁸-A¹⁹-A²⁰-A²¹-A²²-A²³-A²⁴-A²⁵-A²⁶-A²⁷-A²⁸-A²⁹-A³⁰-A³¹-A³²-A³³-A³⁴-A³⁵-A³⁶-A³⁷-A³⁸-A³⁹-A⁴⁰-P² (1), en donde cada símbolo es como se define en la presente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017072556 | 2017-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR111346A1 true AR111346A1 (es) | 2019-07-03 |
Family
ID=62089992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180100762A AR111346A1 (es) | 2017-03-31 | 2018-03-28 | Compuesto peptídico con acción activante sobre receptores gip |
Country Status (21)
Country | Link |
---|---|
US (2) | US10435445B2 (es) |
EP (1) | EP3601329A1 (es) |
JP (2) | JP7175912B2 (es) |
KR (1) | KR20190134626A (es) |
CN (1) | CN110709414A (es) |
AR (1) | AR111346A1 (es) |
AU (2) | AU2018246553B2 (es) |
BR (1) | BR112019020438A2 (es) |
CA (1) | CA3058361A1 (es) |
CL (1) | CL2019002790A1 (es) |
CO (1) | CO2019012271A2 (es) |
EA (1) | EA201992327A1 (es) |
EC (1) | ECSP19078239A (es) |
IL (1) | IL269581B2 (es) |
JO (2) | JOP20180028A1 (es) |
MA (1) | MA48998A (es) |
PE (1) | PE20200675A1 (es) |
PH (1) | PH12019502252A1 (es) |
SG (1) | SG11201908542QA (es) |
TW (1) | TWI801373B (es) |
WO (1) | WO2018181864A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020067557A2 (en) * | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
WO2020067575A1 (en) * | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
TWI764209B (zh) | 2019-08-01 | 2022-05-11 | 美商美國禮來大藥廠 | Gipr促效劑化合物 |
AU2021229621B2 (en) * | 2020-03-06 | 2023-08-31 | Sanofi | Peptides as selective GIP receptor agonists |
IL296219A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Weekly doses of gip receptor agonist peptides and their uses |
CN115335395A (zh) * | 2020-03-25 | 2022-11-11 | 武田药品工业株式会社 | Gip受体激动剂肽化合物的qd给药及其用途 |
US20230127047A1 (en) | 2020-03-31 | 2023-04-27 | Antaros Medical Ab | Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes |
CA3184717A1 (en) | 2020-07-22 | 2022-01-27 | Patrick J. KNERR | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
CN117866049A (zh) * | 2021-05-28 | 2024-04-12 | 广东众生睿创生物科技有限公司 | 多肽的制备及其应用 |
AU2022339059A1 (en) | 2021-09-06 | 2024-05-02 | Sanofi | New peptides as potent and selective gip receptor agonists |
EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
CN116891522B (zh) * | 2022-04-01 | 2024-05-14 | 南京知和医药科技有限公司 | 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途 |
WO2023193727A1 (zh) * | 2022-04-07 | 2023-10-12 | 广东众生睿创生物科技有限公司 | 多肽在制备治疗和/或预防糖尿病及肥胖症及其相关疾病药物中的制药用途 |
EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Gip様活性を有するポリペプチド誘導体及びその用途 |
CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
DE60006100T2 (de) | 1999-05-17 | 2004-07-01 | Conjuchem, Inc., Montreal | Lang wirkende insulinotrope peptide |
AU2001269531A1 (en) | 2000-07-17 | 2002-01-30 | Takeda Chemical Industries Ltd. | Sulfone derivatives, process for their production and use thereof |
US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
KR20050062645A (ko) | 2002-11-01 | 2005-06-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 신경병증의 예방 또는 치료제 |
WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
EP1564213A4 (en) | 2002-11-22 | 2009-05-27 | Takeda Pharmaceutical | IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF |
WO2004106276A1 (ja) | 2003-05-30 | 2004-12-09 | Takeda Pharmaceutical Company Limited | 縮合環化合物 |
US7534887B2 (en) | 2003-09-30 | 2009-05-19 | Takeda Pharmaceutical Company Limited | Thiazoline derivative and use of the same |
JP4769082B2 (ja) | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | ウレア誘導体、その製造法及び用途 |
WO2005063729A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
US7517910B2 (en) | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
SG159551A1 (en) | 2005-02-11 | 2010-03-30 | Amylin Pharmaceuticals Inc | Gip analog and hybrid polypeptides with selectable properties |
JP5094394B2 (ja) | 2005-04-20 | 2012-12-12 | 武田薬品工業株式会社 | 縮合複素環化合物 |
WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
WO2007013694A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | フェノキシアルカン酸化合物 |
EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
RU2008108984A (ru) | 2005-08-10 | 2009-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Терапевтический агент от диабета |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
EP1937716A2 (en) | 2005-09-08 | 2008-07-02 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
US20090170762A1 (en) | 2005-09-08 | 2009-07-02 | Uutech Limited | Treatment of Diabetes Related Obesity |
US20090186817A1 (en) | 2006-03-21 | 2009-07-23 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
TWI354668B (en) | 2006-06-27 | 2011-12-21 | Takeda Pharmaceutical | Fused cyclic compounds |
EP2057188B1 (en) | 2006-08-17 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Dpp-iv resistant gip hybrid polypeptides with selectable properties |
US8497240B2 (en) * | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
EP2077267A4 (en) | 2006-10-18 | 2010-04-07 | Takeda Pharmaceutical | FUSED HETEROCYCLIC COMPOUND |
BRPI0717722A2 (pt) | 2006-10-19 | 2013-10-29 | Takeda Pharmaceutical | Composto ou um sal do mesmo, pró-droga, ativador de glicoquinase, agente farmacêutico, métodos para ativar uma glicoquinase em um mamífero e para a profilaxia ou o tratamento de diabetes ou obesidade em um mamífero, e, uso do composto ou uma pró-droga do mesmo |
EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
BRPI0807014A2 (pt) | 2007-02-09 | 2014-04-22 | Takeda Pharmaceutical | Composto, pró-droga, agente farmacêutico, métodos para melhorar a resistência a insulina em um mamífero, método para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso de um composto. |
US8318746B2 (en) | 2007-04-27 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Nitrogen-containing five-membered heterocyclic compound |
US20110301155A1 (en) | 2007-06-19 | 2011-12-08 | Tsuneo Yasuma | Indazole compounds for activating glucokinase |
WO2009042922A2 (en) | 2007-09-27 | 2009-04-02 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
ES2558842T3 (es) | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
EA020005B1 (ru) | 2008-08-07 | 2014-07-30 | Ипсен Фарма С.А.С. | Аналоги глюкозазависимого инсулинотропного полипептида |
KR101417873B1 (ko) | 2008-08-07 | 2014-07-09 | 입센 파마 에스.에이.에스 | 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체 |
JP2011530506A (ja) | 2008-08-07 | 2011-12-22 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | グルコース依存性インスリン分泌刺激ポリペプチドの切り詰められたアナログ |
AU2009280021B2 (en) | 2008-08-07 | 2012-10-04 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
JP2012512903A (ja) | 2008-12-19 | 2012-06-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | アミド系グルカゴンスーパーファミリーペプチドプロドラッグ |
KR20120087875A (ko) | 2009-06-16 | 2012-08-07 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체-활성 글루카곤 화합물 |
WO2011014680A2 (en) | 2009-07-31 | 2011-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Gastric inhibitory peptide variants and their uses |
JP2013518115A (ja) | 2010-01-27 | 2013-05-20 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐gipアゴニスト複合体及び組成物 |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
EP2654774A4 (en) | 2010-12-22 | 2015-07-01 | Marcadia Biotech Inc | METHOD FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS WITH GIP AND GLP-1 RECEPTOR ACTIVE PUCIDIDES ON GLUCAGON BASIS |
NZ612297A (en) | 2010-12-22 | 2015-10-30 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
CN103764673A (zh) | 2011-06-10 | 2014-04-30 | 北京韩美药品有限公司 | 葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用 |
US20130090285A1 (en) | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
CN104470948B (zh) | 2012-05-03 | 2018-06-15 | 西兰制药公司 | Gip-glp-1双激动剂化合物及方法 |
JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Gip受容体活性を示すグルカゴンアナローグ |
AU2013277372B2 (en) | 2012-06-21 | 2018-03-29 | Indiana University Research And Technology Corporation | Analogs of glucagon exhibiting GIP receptor activity |
CN104902919B (zh) | 2012-12-21 | 2018-11-20 | 赛诺菲 | Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂 |
MY172744A (en) * | 2013-05-28 | 2019-12-11 | Takeda Pharmaceuticals Co | Peptide compound |
US20160185837A1 (en) | 2013-08-16 | 2016-06-30 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
JP6682432B2 (ja) | 2013-11-06 | 2020-04-15 | ジーランド ファーマ アクティーゼルスカブ | Gip−glp−1デュアルアゴニスト化合物及び方法 |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
EP3530671A3 (en) | 2014-09-05 | 2019-11-13 | University of Copenhagen | Gip peptide analogues |
US10253078B2 (en) | 2014-10-29 | 2019-04-09 | Zealand Pharma A/S | GIP agonist compounds and methods |
WO2016077220A1 (en) | 2014-11-10 | 2016-05-19 | Mb2 Llc | Gip/glp-1 co-agonist peptides for human administration |
JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
JP6326394B2 (ja) | 2015-10-09 | 2018-05-16 | Kyb株式会社 | ミキサ車の積載量計量装置 |
CN108473547A (zh) | 2015-10-28 | 2018-08-31 | 塔夫茨大学 | 具有改良的蛋白质分解安定性的新颖多肽,以及制备与使用该新颖多肽的方法 |
PE20181494A1 (es) | 2015-12-31 | 2018-09-18 | Hanmi Pharm Ind Co Ltd | Conjugado persistente de triple activador que activa el receptor de glucagon, glp-1 u gip |
JP6995042B2 (ja) | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | ペプチド化合物 |
-
2017
- 2017-03-31 JO JOP/2018/0028A patent/JOP20180028A1/ar unknown
- 2017-06-16 JO JOP/2019/0211A patent/JOP20190211A1/ar unknown
-
2018
- 2018-03-28 AR ARP180100762A patent/AR111346A1/es unknown
- 2018-03-30 CN CN201880035168.2A patent/CN110709414A/zh active Pending
- 2018-03-30 TW TW107111293A patent/TWI801373B/zh active
- 2018-03-30 IL IL269581A patent/IL269581B2/en unknown
- 2018-03-30 JP JP2019553587A patent/JP7175912B2/ja active Active
- 2018-03-30 CA CA3058361A patent/CA3058361A1/en active Pending
- 2018-03-30 SG SG11201908542Q patent/SG11201908542QA/en unknown
- 2018-03-30 AU AU2018246553A patent/AU2018246553B2/en active Active
- 2018-03-30 EP EP18721166.9A patent/EP3601329A1/en active Pending
- 2018-03-30 KR KR1020197028353A patent/KR20190134626A/ko not_active Application Discontinuation
- 2018-03-30 EA EA201992327A patent/EA201992327A1/ru unknown
- 2018-03-30 BR BR112019020438A patent/BR112019020438A2/pt unknown
- 2018-03-30 WO PCT/JP2018/013540 patent/WO2018181864A1/en active Application Filing
- 2018-03-30 US US15/941,030 patent/US10435445B2/en active Active
- 2018-03-30 MA MA048998A patent/MA48998A/fr unknown
- 2018-03-30 PE PE2019001962A patent/PE20200675A1/es unknown
-
2019
- 2019-08-29 US US16/555,085 patent/US11174301B2/en active Active
- 2019-09-30 CL CL2019002790A patent/CL2019002790A1/es unknown
- 2019-09-30 PH PH12019502252A patent/PH12019502252A1/en unknown
- 2019-10-30 EC ECSENADI201978239A patent/ECSP19078239A/es unknown
- 2019-10-31 CO CONC2019/0012271A patent/CO2019012271A2/es unknown
-
2022
- 2022-02-09 AU AU2022200837A patent/AU2022200837A1/en not_active Abandoned
- 2022-11-09 JP JP2022179703A patent/JP2023012547A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL269581A (en) | 2019-11-28 |
CL2019002790A1 (es) | 2020-05-29 |
WO2018181864A1 (en) | 2018-10-04 |
US20200140505A1 (en) | 2020-05-07 |
US20180298070A1 (en) | 2018-10-18 |
US11174301B2 (en) | 2021-11-16 |
JOP20190211A1 (ar) | 2019-09-15 |
IL269581B1 (en) | 2024-02-01 |
AU2018246553B2 (en) | 2021-11-11 |
US10435445B2 (en) | 2019-10-08 |
EP3601329A1 (en) | 2020-02-05 |
CA3058361A1 (en) | 2018-10-04 |
BR112019020438A2 (pt) | 2020-06-09 |
AU2018246553A1 (en) | 2019-10-17 |
CN110709414A (zh) | 2020-01-17 |
AU2022200837A1 (en) | 2022-03-03 |
PE20200675A1 (es) | 2020-06-11 |
EA201992327A1 (ru) | 2020-02-19 |
CO2019012271A2 (es) | 2020-08-21 |
IL269581B2 (en) | 2024-06-01 |
JP2023012547A (ja) | 2023-01-25 |
KR20190134626A (ko) | 2019-12-04 |
MA48998A (fr) | 2020-02-05 |
ECSP19078239A (es) | 2019-12-27 |
PH12019502252A1 (en) | 2020-06-29 |
JP7175912B2 (ja) | 2022-11-21 |
JOP20180028A1 (ar) | 2019-01-30 |
TWI801373B (zh) | 2023-05-11 |
SG11201908542QA (en) | 2019-10-30 |
TW201841936A (zh) | 2018-12-01 |
JP2020515612A (ja) | 2020-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR111346A1 (es) | Compuesto peptídico con acción activante sobre receptores gip | |
DOP2015000261A (es) | Compuesto peptídico como activador de los receptores del glp-1 y del gip | |
CL2019000542A1 (es) | Compuestos de tetraciclina y métodos de uso de los mismos. | |
CO2020001879A2 (es) | Compuesto heterocíclico y su uso | |
CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
UY35821A (es) | Compuesto heterocíclico | |
AR094309A1 (es) | Compuesto heterociclico fusionado y uso del mismo para el control de plagas | |
CR20180141A (es) | Anticuerpos anti-cd 19 humano humanizados y métodos de utilización | |
CR20160502A (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso | |
BR112018075736A2 (pt) | composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1 | |
UY37153A (es) | Sulfonilamidas sustituidas para combatir parásitos animales | |
ECSP16096831A (es) | Derivados de naftiridinadiona | |
UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
TR201901516T4 (tr) | Nöroprotektif ajanlar ve bunların kullanımları. | |
CL2020001252A1 (es) | Métodos de uso y composiciones que contienen dulaglutida. | |
RU2013142539A (ru) | Ароматические полиэфиры | |
CL2017001258A1 (es) | Generación de inmunidad | |
CL2019000572A1 (es) | Compuesto de imida y uso del mismo. | |
GT201700025S (es) | Contenedor epóxico | |
DOP2017000016A (es) | Nueva sal de disoproxilo de tenofovir | |
CR20150533A (es) | Compuesto peptídico | |
RU2013142538A (ru) | Ароматические полиэфирсульфонкетоны | |
UA112287U (xx) | Застосування вінборону для нівелювання антипроліферативного впливу ібупрофену на шлунковий епітелій | |
CL2017000315S1 (es) | Sostén libre de sujetador en la espalda. | |
BR112017027137A2 (pt) | reguladores de nrf2 |